21 A novel flurophore-cyano-carboxylic-Ag microhybrid: Enhanced two photon absorption for two-photon photothermal therapy of HeLa cancer cells by targeting mitochondria.

22 Adjuvant quercetin therapy for combined treatment of epilepsy and comorbid depression.

23 Targeting mitochondria with Au-Ag@Polydopamine nanoparticles for papillary thyroid cancer therapy.

24 Ordering a selected Zn(II), Cu(II), Pd(II) and Co(III) complex compounds. Their separately and combinedly antibacterial therapy and DNA-binding studies.

25 Synthetic lethal interaction between oxidative stress response and DNA damage repair in the budding yeast and its application to targeted anticancer therapy.

26 Fabrication of silver seeds and nanoparticle on core-shell Ag@SiO<inf>2</inf> nanohybrids for combined photothermal therapy and bioimaging

27 Determination of the activity of uracil-DNA glycosylase by using two-tailed reverse transcription PCR and gold nanoparticle-mediated silver nanocluster fluorescence: a new method for gene therapy-related enzyme detection

28 Recommendations for Regulating the Environmental Risk of Shedding for Gene Therapy and Oncolytic Viruses in Canada.

29 The development of a time-based nursing information system in dermatology outpatients and day therapy areas.

30 Tumor-Microenvironment-Induced All-in-One Nanoplatform for Multimodal Imaging-Guided Chemical and Photothermal Therapy of Cancer.

31 Adjuvant quercetin therapy for combined treatment of epilepsy and comorbid depression.

32 Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy.

33 Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.

34 Novel design of NIR-triggered plasmonic nanodots capped mesoporous silica nanoparticles loaded with natural capsaicin to inhibition of metastasis of human papillary thyroid carcinoma B-CPAP cells in thyroid cancer chemo-photothermal therapy.

35 Intracellular dark-field imaging of ATP and photothermal therapy using a colorimetric assay based on gold nanoparticle aggregation via tetrazine/trans-cyclooctene cycloaddition.

36 Gold nanoparticle based photothermal therapy: Development and application for effective cancer treatment

37 PEG-derivatized birinapant as a nanomicellar carrier of paclitaxel delivery for cancer therapy.

38 Challenges and Contradictions of Metal Nano-Particle Applications for Radio-Sensitivity Enhancement in Cancer Therapy.

39 Evaluation of Continuous Renal Replacement Therapy and Therapeutic Plasma Exchange, in Severe Sepsis or Septic Shock in Critically Ill Children.

40 Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish.

41 Dispensation of antiretroviral therapy and methadone maintenance therapy at the same facility in a low-barrier setting linked to optimal adherence to HIV treatment.

42 Potential Negative Effects of Dextromethorphan as an Add-On Therapy to Methylphenidate in Children With ADHD.

43 Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.

44 Effects of cognitive behavioral therapy on psychological adjustment in Chinese pediatric cancer patients receiving chemotherapy: A randomized trial.

45 Initial Experience of Pembrolizumab Therapy in Japanese Patients With Metastatic Urothelial Cancer.

46 Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population.

47 Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy

48 Testing the role of vitamin D in response to antitumour necrosis factor α therapy in a UK cohort: a Mendelian randomisation approach.

49 Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.

50 Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.

51 Thromboembolic, Bleeding, and Mortality Risks among Patients with Nonvalvular Atrial Fibrillation Treated with Dual Antiplatelet Therapy versus Oral Anticoagulants: A Population-Based Study.

52 Economic evaluation of the use of non-Vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: A modelling analysis using the healthcare system in the Netherlands

53 Outcomes of intraparenchymal hemorrhage after direct oral anticoagulant or vitamin K antagonist therapy: A systematic review and meta-analysis

54 Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients

55 The Effect of Vacuum-Assisted Closure Therapy on Methicillin-Resistant Staphylococcus aureus Wound Biofilms.

56 Pharmacological Properties of the Medical Maggot: A Novel Therapy Overview.

57 Low-level laser therapy as an antimicrobial and antibiofilm technology and its relevance to wound healing

58 Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy

59 Conventional oral and secondary high dose vaginal metronidazole therapy for recurrent bacterial vaginosis: clinical outcomes, impacts of sex and menses

60 Staphyloxanthin: a potential target for antivirulence therapy

61 Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy

62 In vitro and in vivo activity of ciprofloxacin/fosfomycin combination therapy against ciprofloxacin-resistant Shigella flexneri isolates

63 Direct use of eazyplex® SuperBug CRE assay from positive blood cultures in conjunction with inpatient infectious disease consulting for timely appropriate antimicrobial therapy in Escherichia coli and Klebsiella pneumoniae bloodstream infections

64 Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

65 Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

66 Outpatient ertapenem therapy in an ESBL-high-prevalence area: an efficacy, safety, and cost study

67 Efficacy of φkm18p phage therapy in a murine model of extensively drug-resistant Acinetobacter baumannii infection

68 Community acquired pneumonia among adult patients at an Egyptian university hospital: bacterial etiology, susceptibility profile and evaluation of the response to initial empiric antibiotic therapy

69 Malaria parasite clearance from patients following artemisinin-based combination therapy in Côte d’Ivoire

70 Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections

71 Optimal infusion rate in antimicrobial therapy: explosion of evidence in the last five years

72 Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

73 In vitro antibacterial effect of fosfomycin combination therapy against colistin-resistant Klebsiella pneumoniae

74 Antimicrobial use of reactive oxygen therapy: current insights

75 Current eradication rate of Helicobacter pylori with clarithromycin-based triple therapy in a gastroenterology practice in the New York metropolitan area

76 In vitro activity of colistin mono- and combination therapy against colistin-resistant Acinetobacter baumannii, mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant A. baumannii at a Thai university hospital

77 Probiotics improve the efficacy of standard triple therapy in the eradication of Helicobacter pylori: a meta-analysis

78 Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy

79 Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm

80 Outpatient parenteral antimicrobial therapy with ceftriaxone for acute tonsillopharyngitis: efficacy, patient satisfaction, cost effectiveness, and safety

81 Antibiotic lock therapy: review of technique and logistical challenges

82 Optimizing antimicrobial therapy in critically ill patients

83 Update on management options in the treatment of nosocomial and ventilator assisted pneumonia: review of actual guidelines and economic aspects of therapy

84 Molecular analysis of markers associated with chloroquine and sulfadoxine/pyrimethamine resistance in Plasmodium falciparum malaria parasites from southeastern Côte-d'Ivoire by the time of Artemisinin-based Combination Therapy adoption in 2005

85 Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients

86 Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy

87 The use of anti-tuberculosis therapy for latent TB infection

88 Which thiazide to choose as add-on therapy for hypertension?

89 Current perspectives on combination therapy in the management of hypertension

90 Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination

91 Long-acting nifedipine for hypertensive patients in the Middle East and Morocco: observations on efficacy and tolerability of monotherapy or combination therapy

92 Azilsartan/chlorthalidone combination therapy for blood pressure control

93 De-stiffening drug therapy and blood pressure control

94 Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors

95 Valsartan combination therapy in the management of hypertension – patient perspectives and clinical utility

96 Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions

97 Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies

98 Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

99 Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy

100 Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma

101 Guideline-recommended therapy, including beta-blocker utilization, in patients with chronic heart failure: results from a Canadian community hospital heart function clinic

Keyword Connections

Journals

Research Groups

Bibliographies